

DAFTAR PUSTAKA

- American Kidney Fund, 2014. 'Kidney Disease Statistics', . URL:
<http://www.kidneyfund.org/kidney-disease/chronic-kidney-disease-ckd/>.
- Andayani, T.M., 2013. *Farmakoekonomi Prinsip Dan Metodologi*. Bursa Ilmu, Yogyakarta.
- Anees, M., Hameed, F., Mumtaz, A., Ibrahim, M., dan Saeed Khan, M.N., 2011. Dialysis-related factors affecting quality of life in patients on hemodialysis. *Iranian Journal of Kidney Diseases*, **5**: 9–14.
- Armiyati, Y. dan Rahayu, D.A., 2014. 'FAKTOR YANG BERKORELASI TERHADAP MEKANISME KOPING PASIEN CKD YANG MENJALANI HEMODIALISIS DI RSUD KOTA SEMARANG (Correlating factors of coping mechanism on CKD patients undergoing Hemodialysis in RSUD Kota Semarang)', , dalam: *PROSIDING SEMINAR NASIONAL & INTERNASIONAL*.
- Arnold, R.J.G., 2009. *Pharmacoeconomics : From Theory to Practice*, 1st ed. CRC Press, United State of America.
- Bernard, L., Mendelssohn, D., Dunn, E., Hutchison, C., dan Grima, D.T., 2013. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. *Journal of Medical Economics*, **16**: 1–9.
- Block, G.A., 2004. Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. *Journal of the American Society of Nephrology*, **15**: 2208–2218.
- Block, G.A., Spiegel, D.M., Ehrlich, J., Mehta, R., Lindbergh, J., Dreisbach, A., dkk., 2005. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis - pdf. *Kidney International*, **68**: 1815–1824.
- Bodrogi, J. dan Kaló, Z., 2010. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. *British Journal of Pharmacology*, **159**: 1367–1373.
- Bootman, J., Townsend, R., dan McGhan, W., 2005. *Principles of Pharmacoeconomics*, 3rd ed. Harvey Whitney Books Company, Cincinnati.

- CDC, 2015. 'National Chronic Kidney Disease Fact Sheet, 2014', https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf.
- Chen, N., Wu, X., Ding, X., Mei, C., Fu, P., Jiang, G., dkk., 2014. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. *Nephrology Dialysis Transplantation*, **29**: 152–160.
- Chertow, G.M., Burke, S.K., Dillon, M.A., Slatopolsky, E., dan Group, for the R.S., 1999. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. *Nephrology Dialysis Transplantation*, **14**: 2907–2914.
- Chiu, Y.-W., Teitelbaum, I., Misra, M., de Leon, E.M., Adzize, T., dan Mehrotra, R., 2009. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. *Clinical Journal of the American Society of Nephrology*, **4**: 1089–1096.
- Coladonato, J.A., 2005. Control of Hyperphosphatemia among Patients with ESRD. *Journal of the American Society of Nephrology*, **16**: S107–S114.
- Cupisti, A., Gallieni, M., Rizzo, M.A., Caria, S., Meola, M., dan Bolasco, P., 2013. Phosphate control in dialysis. *International Journal of Nephrology and Renovascular Disease*, **6**: 193–205.
- Davies, E.W., Matza, L.S., Worth, G., Feeny, D.H., Kostelec, J., Soroka, S., dkk., 2015. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. *Health and Quality of Life Outcomes*, **13**: .
- Dewi, S.P., 2015. 'Hubungan Lamanya Hemodialisa dengan Kualitas Hidup Pasien Gagal Ginjal di RS PKU Muhammadiyah Yogyakarta', . STIKES' Aisyiyah Yogyakarta.
- Di Iorio, B., Molony, D., Bell, C., Cucciniello, E., Bellizzi, V., Russo, D., dkk., 2013. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial. *American Journal of Kidney Diseases*, **62**: 771–778.
- Dirjen Bina Kefarmasian dan Alat Kesehatan, 2013. *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan RI, Jakarta.

- Dowling, T.C., 2008. Quantification of Renal Function, dalam: *Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, New York, hal. 705–720.
- Eknoyan, G., Lameire, N., dan Eckardt, K.-U., 2013. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Internatioanl Society of Nephrology*, **3**: .
- Eknoyan, G., Levin, A., dan Levin, N.W., 2003. K/DOQI Clinical Practice Guideline for Bone Metabolism and Disease in Chronic Kidney Disease. *American Journal of Kidney Diseases*, **42**: S1–S170.
- Endarti, D., Riewpaiboon, A., Thavorncharoensap, M., Praditsitthikorn, N., Hutubessy, R., dan Kristina, S.A., 2015. Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia. *Asian Pacific Journal of Cancer Prevention*, **16**: 3345–3350.
- EuroQol Group, 2016. 'EuroQol - EQ-5D-5L', . URL: <http://www.euroqol.org/eq-5d-products/eq-5d-5l.html> (diakses tanggal 16/1/2017).
- Faridah, A., Jamaiyah, H., Goh, A., Soraya, A., dan others, 2010. The validation of the EQ-5D in Malaysian dialysis patients. *Med J Malaysia*, **65**: 114–119.
- Finn, W.F., 2005. 'Phosphorus Binders: Relative Potency : Phosphate-Binding Agents', . URL: http://www.medscape.org/viewarticle/506489_3 (diakses tanggal 17/1/2017).
- Frazão, C.M.F. de Q., de Sá, J.D., Medeiros, A.B. de A., Fernandes, M.I. da C.D., Lira, A.L.B. de C., dan Lopes, M.V. de O., 2014. The adaptation problems of patients undergoing hemodialysis: socio-economic and clinical aspects. *Revista Latino-Americana de Enfermagem*, **22**: 966–972.
- Fröschl, B., Brunner-Ziegler, S., Hiebinger, C., Wimmer, A., dan Zsifkovits, J., 2009. Effectiveness and cost-efficiency of phosphate binders in hemodialysis. *GMS health technology assessment*, **5**: .
- Galante, J., Augustovski, F., Colantonio, L., Bardach, A., Caporale, J., Marti, S.G., dkk., 2011. Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. *Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, **14**: S60-64.

- Gerogianni, S.K. dan Babatsikou, F.P., 2014. Psychological Aspects in Chronic Renal Fail. *Health science journal*, **8**: .
- Goldberg, I. dan Krause, I., 2016. THE ROLE OF GENDER IN CHRONIC KIDNEY DISEASE. *EMJ*, **1**: 58–64.
- Goto, S., Komaba, H., Moriwaki, K., Fujimori, A., Shibuya, K., Nishioka, M., dkk., 2011. Clinical Efficacy and Cost-Effectiveness of Lanthanum Carbonate as Second-Line Therapy in Hemodialysis Patients in Japan. *Clinical Journal of the American Society of Nephrology*, **6**: 1375–1384.
- Grinfeld, J., Inaba, A., dan Hutchison, A.J., 2010. Update and critical appraisal of sevelamer in the management of chronic renal failure. *Open Access Journal of Urology*, **2**: 161–170.
- Haryani, I.E. dan Probandari, A., 2013. 'ANALISIS BIAYA RAWAT JALAN HEMODIALISIS DAN PERITONEAL DIALISIS MANDIRI BERKESINAMBUNGAN PADA PESERTA ASKES DI PT. ASKES (PERSERO) DIVISI REGIONAL VI', . Universitas Gadjah Mada.
- Hudson, M.S., 2008. Chronic Kidney Disease : Management of Complications, dalam: *Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, New York, hal. 765–768.
- Hutchison, A.J., 2009. Oral phosphate binders. *Kidney international*, **75**: 906–914.
- Huybrechts, K.F., Caro, J.J., Wilson, D.A., dan O'Brien, J.A., 2005. Health and Economic Consequences of Sevelamer Use for Hyperphosphatemia in Patients on Hemodialysis. *Value in Health*, **8**: 549–561.
- Iseki, K., Tozawa, M., dan Takishita, S., 2003. Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients. *Nephrology Dialysis Transplantation*, **18**: 782–787.
- Javanbakht, M., Abolhasani, F., Mashayekhi, A., Baradaran, H.R., dan Jahangiri noudeh, Y., 2012. Health Related Quality of Life in Patients with Type 2 Diabetes Mellitus in Iran: A National Survey. *PLoS ONE*, **7**: .
- Jhita, T., Petrou, S., Gumber, A., Szczepura, A., Raymond, N.T., dan Bellary, S., 2014. Ethnic differences in health related quality of life for patients with type 2 diabetes. *Health and Quality of Life Outcomes*, **12**: 83.

- Johansen, K.L. dan Chertow, G.M., 2007. Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD) and Health-Related Quality of Life among Incident ESRD Patients. *Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation*, **17**: 305–313.
- Jonjic, N., Djordjevic, V., Djordjevic, N., dan Ljubenovic, S., 2008. Effect of the hemodialysis duration, age and gender on the emergence of the renal osteodystrophy symptoms. *Acta Medica Medianae*, **47**: 19–24.
- Joy, M.S., Khirsagar, A., dan Franceschini, G.C., 2008. Chronic Kidney Disease : Progression-Modifying Therapies, dalam: *Pharmacotherapy A Pathophysiologic Approach*. McGraw Hill Professional, New York, hal. 745–750.
- Katayama, A., Miyatake, N., Nishi, H., Uzike, K., Sakano, N., Hashimoto, H., dkk., 2014. Evaluation of physical activity and its relationship to health-related quality of life in patients on chronic hemodialysis. *Environmental Health and Preventive Medicine*, **19**: 220–225.
- Kazancioğlu, R., 2013. Risk factors for chronic kidney disease: an update. *Kidney International Supplements*, **3**: 368–371.
- KDIGO, 2009. KDIGO Clinical Practice Guideline for The Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Journal of The International Society of Nephrology*, **76**: S1–S120.
- KDIGO, 2012. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*, **2**: 1.
- Keliat, B. dan Akemat, 2009. *Model Praktik Keperawatan Profesional Jiwa*. EGC, Jakarta.
- Kementerian Kesehatan RI, 2013. 'RISET KESEHATAN DASAR (RISKESDAS) 2013', . Kementerian Kesehatan RI, Jakarta.
- Kooienga, L. dan Moore, R., 2008. Sevelamer carbonate in the management of hyperphosphatemia. *Therapy*, **5**: 545–552.
- Kumar, S. dan Baldi, A., 2013. Pharmacoeconomics: Principles, Methods and Economic Evaluation of Drug Therapies. *TechMed*, **2**: 362–369.

- Lahana, E. dan Niakas, D., 2013. Investigating Differences in Health-Related Quality of Life of Greeks and Albanian Immigrants with the Generic EQ-5D Questionnaire. *BioMed Research International*, **2013**: .
- Lemeshow, S., Hosmer, D.W., Klar, J., dan Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. John Wiley & Sons Ltd., Inggris.
- Liem, Y.S., Bosch, J.L., dan Myriam Hunink, M.G., 2008. Preference-Based Quality of Life of Patients on Renal Replacement Therapy: A Systematic Review and Meta-Analysis. *Value in Health*, **11**: 733–741.
- Lih-Wen Mau, Heng-Chiu Chiu, Pi-Yu Chang, Su-Chen Hwang, dan Shang-Jyh Hwang, 2008. Health-related quality of life in Taiwanese dialysis patients: effects of dialysis modality. *Kaohsiung J Med Sci*, **24**: 453–460.
- Liu, C.K., Lyass, A., Massaro, J.M., D’Agostino, R.B., Fox, C.S., dan Murabito, J.M., 2014. Chronic Kidney Disease Defined by Cystatin C Predicts Mobility Disability and Changes in Gait Speed: The Framingham Offspring Study. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, **69A**: 301–307.
- Makkar, V., Kumar, M., Mahajan, R., dan Khaira, N.S., 2015. Comparison of Outcomes and Quality of Life between Hemodialysis and Peritoneal Dialysis Patients in Indian ESRD Population. *Journal of Clinical and Diagnostic Research : JCDR*, **9**: OC28-OC31.
- Manns, B., Stevens, L., Miskulin, D., Owen, W.F., Winkelmayr, W.C., dan Tonelli, M., 2004. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. *Kidney international*, **66**: 1239–1247.
- Mason, D.L. dan Assimon, M.L. (Editor), 2013. Chronic Kidney Disease, dalam: *Applied Therapeutics: The Clinical Use of Drugs*. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia.
- Matsushita, K., Sato, K., Unagami, K., Nitta, K., dan Tago, K., 2014. Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients. *International Journal of Clinical Medicine*, **05**: 1320–1327.

- Michels, T.C. dan Kelly, K.M., 2013. Parathyroid disorders. *Am Fam Physician*, **88**: 249–257.
- Nadin, C., 2004. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value. *Core evidence*, **1**: 43–63.
- National Kidney Foundation, 2002. *Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification*. National Kidney Foundation, New York.
- National Kidney Foundation, 2015. 'Dialysis', *The National Kidney Foundation*. URL: <https://www.kidney.org/atoz/content/dialysisinfo> (diakses tanggal 25/1/2017).
- Nguyen, H.V., Bose, S., dan Finkelstein, E., 2016. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. *BMC Nephrology*, **17**: .
- NHS, 2013. Hyperphosphataemia in chronic kidney disease : Management of Hyperphosphataemia in patients with stage 4 or 5 chronic kidney disease.
- Nurchayati, S., 2010. 'Analisis Faktor-Faktor Yang Berhubungan dengan Kualitas Hidup Pasien Penyakit Ginjal Kronik yang Menjalani Hemodialisis di Rumah Sakit Islam Fatimah Cilacap dan Rumah Sakit Umum Banyumas', , *Tesis*, . Universitas Indonesia, Jakarta.
- Nurika, M., 2014. 'Hubungan Terapi Kalsium Karbonat terhadap Kadar Hormon Paratiroid Intak pada Pasien Hemodialisis Rutin di Rumah Sakit Akademik UGM Yogyakarta', , *Tesis*, . Universitas Gadjah Mada, Yogyakarta.
- Octawati, I., 2005. 'Profil Kadar Hormon Paratiroid, Kalsium, Dan Fosfat Pada Pasien Gagal Ginjal Kronik Yang Dilakukan Tindakan Hemodialisis Di Rumah Sakit Dr. Sardjito Yogyakarta', , *Tesis*, . Universitas Gadjah Mada, Yogyakarta.
- O'Hare, A.M., Choi, A.I., Bertenthal, D., Bacchetti, P., Garg, A.X., Kaufman, J.S., dkk., 2007. Age Affects Outcomes in Chronic Kidney Disease. *Journal of the American Society of Nephrology*, **18**: 2758–2765.
- Ossareh, S., 2014. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. *International Journal of Nephrology and Renovascular Disease*, 161.

- Park, H., Rascati, K.L., Keith, M.S., Hodgkins, P., Smyth, M., Goldsmith, D., dkk., 2011. Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. *Value in Health*, **14**: 1002–1009.
- Pattanaphesaj, J., 2014. 'Health-Related Quality of Life Measure (EQ-5D-5L): Measurement Property Testing and Its Preference-Based Score in Thai Population', , *Doctoral Dissertation*, . Mahidol University, Thailand.
- PERNEFRI, 2014. '7th Report of Indonesian Renal Registry', <http://www.indonesianrenalregistry.org/data/INDONESIAN%20RENAL%20REGISTRY%202014.pdf>.
- Pham, P.-C.T., Toscano, E., Pham, P.-M.T., Pham, P.-A.T., Pham, S.V., dan Pham, P.-T.T., 2009. Pain management in patients with chronic kidney disease. *NDT Plus*, **2**: 111–118.
- Pierce, D., Hossack, S., Poole, L., Robinson, A., Van Heusen, H., Martin, P., dkk., 2011. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. *Nephrology Dialysis Transplantation*, **26**: 1615–1621.
- Preljevic, V.T., Østhus, T.B.H., Os, I., Sandvik, L., Opjordsmoen, S., Nordhus, I.H., dkk., 2013. Anxiety and depressive disorders in dialysis patients: association to health-related quality of life and mortality. *General Hospital Psychiatry*, **35**: 619–624.
- Price, S.A. dan Wilson, L.M., 2006. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*, Edisi 6. ed. Penerbit Buku Kedokteran EGC, Jakarta.
- Prodjosudjadi, W., Suhardjono, A., dan others, 2009. End-stage renal disease in Indonesia: Treatment development. *Ethnicity & disease*, **19**: 33.
- Puspitasari, C.E., 2016. 'Penilaian Kelelahan dan Kualitas Hidup Pasien Hemodialisis Rutin Dengan Anemia Menggunakan Facit-Fatigue Scale dan KDQOL-SF36 di RS UGM dan RSUP Dr. Sardjito Yogyakarta', , *Tesis*, . Univeristas Gadjah Mada, Yogyakarta.
- Rabin, R., Oemar, M., Oppe, M., Janssen, B., dan Herdman, M., 2011. EQ-5D-5L user guide. *Basic information on how to use the EQ-5D-5L instrument*. Rotterdam: EuroQol Group, **22**: .

- Saffari, M., Pakpour, A.H., Naderi, M.K., Koenig, H.G., Baldacchino, D.R., dan Piper, C.N., 2013. Spiritual coping, religiosity and quality of life: a study on Muslim patients undergoing haemodialysis. *Nephrology (Carlton, Vic.)*, **18**: 269–275.
- Sakthong, P. dan Kasemsup, V., 2012. Health Utility Measured with EQ-5D in Thai Patients Undergoing Peritoneal Dialysis. *Value in Health*, **15**: S79–S84.
- Schoolwerth, A.C., Engelgau, M.M., Hostetter, T.H., Rufo, K.H., Chianchiano, D., McClellan, W.M., dkk., 2006. Chronic kidney disease: a public health problem that needs a public health action plan. *Prev Chronic Dis*, **3**: A57.
- Seica, A., Segall, L., Verzan, C., Văduva, N., Madincea, M., Rusoiu, S., dkk., 2009. Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. *Nephrology Dialysis Transplantation*, **24**: 626–629.
- Septiwi, C., 2010. 'Hubungan Antara Adekuasi Hemodialisis Dengan Kualitas Hidup Pasien Hemodialisis di Unit Hemodialisis RS Prof. Dr. Margono Soekarjo Purwokerto', , *Tesis*, . Universitas Indonesia, Jakarta.
- Shaheen, F.A., Akeel, N.M., Badawi, L.S., dan Souqiyeh, M.Z., 2004. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. *Saudi medical journal*, **25**: 785–791.
- Shaman, A.M. dan Kowalski, S.R., 2015. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. *Saudi Pharmaceutical Journal*, .
- Silbiger, S. dan Neugarten, J., 2008. Gender and human chronic renal disease. *ResearchGate*, **5 Suppl A**: S3–S10.
- Singh, H., 2009. Bone disease and calcium abnormalities in elderly patients with CKD. *Am Soc Nephrol Online Curricula: Geriatric Nephrology*, <https://www.asn-online.org/education/distancelearning/curricula/geriatrics/Chapter14.pdf>, .
- Spiegel, B.M.R., Melmed, G., Robbins, S., dan Esrailian, E., 2008. Biomarkers and Health-Related Quality of Life in End-Stage Renal Disease: A Systematic Review. *Clinical Journal of the American Society of Nephrology*, **3**: 1759–1768. S2-2017-387477-bibliography

- Sukandar, E.Y., Andrajati, R., Sigit, J.I., Adnyana, I.K., Setiadi, A.P., dan Kusnandar, 2011. Galag Ginjal Kronik, dalam: *ISO Farmakoterapi 2*. Ikatan Apoteker Indonesia, Jakarta, hal. 345–347.
- Taylor, M.J., Elgazzar, H.A., Chaplin, S., Goldsmith, D., dan Molony, D.A., 2008. An economic evaluation of sevelamer in patients new to dialysis. *Current Medical Research and Opinion*, **24**: 601–608.
- Thavorncharoensap, M., 2014. Measurement of Utility. *J Med Assoc Thai*, **97**: S43–S49.
- The National Kidney Foundation, 2015. 'Global Facts: About Kidney Disease', *The National Kidney Foundation*. URL: <https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease> (diakses tanggal 14/1/2017).
- Thomas, R., Kanso, A., dan Sedor, J.R., 2008. Chronic Kidney Disease and Its Complications. *Primary care*, **35**: 329–vii.
- Tongsiri, S. dan Cairns, J., 2011. Estimating Population-Based Values for EQ-5D Health States in Thailand. *Value in Health*, **14**: 1142–1145.
- Vegter, S., Tolley, K., Keith, M.S., Lok, C.E., Soroka, S.D., dan Morton, A.R., 2012. Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Dialysis Patients: A Canadian Payer Perspective. *Clinical Therapeutics*, **34**: 1531–1543.
- Vogenberg, F., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw Hill Professional, United State of America.
- Wan, E.Y.F., Chen, J.Y., Choi, E.P.H., Wong, C.K.H., Chan, A.K.C., Chan, K.H.Y., dkk., 2015. Patterns of health-related quality of life and associated factors in Chinese patients undergoing haemodialysis. *Health and Quality of Life Outcomes*, **13**: .
- Wandilla, I., 2014. 'Hubungan Kadar Hormon Paratiroid Intak Dengan Kualitas Hidup Pasien Hemodialisis Yang Diberikan Kalsium Karbonat', , *Tesis*, . Univeristas Gadjah Mada, Yogyakarta.
- Wasserfallen, J.-B., Halabi, G., Saudan, P., Perneger, T., Feldman, H.I., Martin, P.-Y., dkk., 2004. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. *Nephrology Dialysis Transplantation*, **19**: 1594–1599.

- Wilson, L.M., 2006. Penyakit Ginjal Stadium kahir : Sindrom Uremik, dalam: *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. Penerbit Buku Kedokteran EGC, Jakarta, hal. 958–960.
- Yang, F., Griva, K., Lau, T., Vathsala, A., Lee, E., Ng, H.J., dkk., 2015. Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. *Quality of Life Research*, **24**: 2163–2171.
- Zyoud, S.H., Daraghme, D.N., Mezyed, D.O., Khdeir, R.L., Sawafta, M.N., Ayaseh, N.A., dkk., 2016. Factors affecting quality of life in patients on haemodialysis: a cross-sectional study from Palestine. *BMC Nephrology*, **17**: .